Author: The Carcinoid Cancer Foundation (CCF)
![asco 2010 2011 expressions of hope calendar](https://i0.wp.com/www.carcinoid.org/wp-content/uploads/2011/07/asco-2010-2011-expressions-of-hope-calendar.jpg?resize=300%2C300&ssl=1)
ASCO Expressions of Hope: Now Accepting Artwork for 2011-2012 Calendar
Carcinoid and neuroendocrine cancer survivors and anyone who has been affected by cancer — patients, friends, families, caregivers — are invited by the American Society of Clinical Oncology (ASCO) to share their emotions through art …
READ MORE![fireworks21](https://i0.wp.com/www.carcinoid.org/wp-content/uploads/2011/07/fireworks21.gif?resize=288%2C183&ssl=1)
Happy 4th of July from The Carcinoid Cancer Foundation
The Carcinoid Cancer Foundation wishes all carcinoid and neuroendocrine tumor survivors, family, caregivers, friends, colleagues, and the medical community who celebrate Independence Day a happy and safe holiday.
… READ MORE
Music for the Carcinoid and Neuroendocrine Tumor Community
What music has been important to you on your journey as a carcinoid neuroendocrine tumor survivor? We asked this question on the Carcinoid Cancer Foundation’s Facebook page and got a wonderful variety of responses that we are sharing here with videos …
READ MORE![MonicaWarner(2) best headshot](https://i0.wp.com/www.carcinoid.org/wp-content/uploads/2011/06/monica20warner202-best-headshot1-scaled.jpg?resize=300%2C300&ssl=1)
Call for Nominations: 2011 Warner Advocacy Award
Novartis Oncology has announced its 2011 Warner Advocacy Award named in honor of Monica Warner, a driving force behind the Carcinoid Cancer Foundation for two decades and an extraordinary advocate for carcinoid and neuroendocrine tumor survivors. …
READ MORECarcinoid Cancer Foundation’s May 2011 Symposium Now Online
The Carcinoid Cancer Foundation is pleased to share with you videos from its carcinoid/NET symposium, “Neuroendocrine Tumor Management: The Era of Personalized Medicine,” held on May 1, 2011 at Mt. Sinai Medical Center in New York City.
Following …
READ MORE![Peter Stothard](https://i0.wp.com/www.carcinoid.org/wp-content/uploads/2011/06/peter-stothard1.jpg?resize=233%2C300&ssl=1)
Worldwide NET Cancer Awareness Day Updates
With less than five months until the second Worldwide NET Cancer Awareness Day on Thursday, November 10, 2011, there have been many exciting developments to share with the carcinoid and NET community.
The first Chinese NET website (www.net.org.tw) …
READ MORE![Zebra](https://i0.wp.com/www.carcinoid.org/wp-content/uploads/2011/06/zebra.jpg?resize=268%2C300&ssl=1)
Now Recruiting: Carcinoid Syndrome Patients to Participate in Clinical Trial
Ipsen is recruiting patients with a history of carcinoid syndrome to participate in a clinical study to evaluate the effect of Somatuline® Depot (Lanreotide Autogel), a somatostatin analog (SSTa) similar to octreotide, on the control of symptoms …
READ MORE![siemens biograph mmr system1](https://i0.wp.com/www.carcinoid.org/wp-content/uploads/2011/06/siemens-biograph-mmr-system1.jpg?resize=300%2C240&ssl=1)
Up-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community
The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100 abstracts on carcinoid…
READ MORE![Cancer.Net mobile](https://i0.wp.com/www.carcinoid.org/wp-content/uploads/2011/05/cancer-net-mobile.jpg?resize=209%2C300&ssl=1)
6 iPhone, Droid, BlackBerry, and iPad Apps for Carcinoid Patients and Physicians
A new iPhone app from ASCO, an app from 3M for physicians to help them manage and keep track of patient data, and the American Cancer Society’s Journals app are some of the newest mobile apps in the areas of medicine and healthcare. For carcinoid and neuroendocrine…
READ MORE![Pfizer logo](https://i0.wp.com/www.carcinoid.org/wp-content/uploads/2011/05/pfizer-logo.jpeg?resize=143%2C86&ssl=1)
Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients
The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread (metastasized) to …
READ MORE